CN101518594A - 一种抗肿瘤及增强免疫力的中药制剂及其制备方法 - Google Patents
一种抗肿瘤及增强免疫力的中药制剂及其制备方法 Download PDFInfo
- Publication number
- CN101518594A CN101518594A CN200910118809A CN200910118809A CN101518594A CN 101518594 A CN101518594 A CN 101518594A CN 200910118809 A CN200910118809 A CN 200910118809A CN 200910118809 A CN200910118809 A CN 200910118809A CN 101518594 A CN101518594 A CN 101518594A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine preparation
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 125
- 238000002360 preparation method Methods 0.000 title claims abstract description 59
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 38
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 20
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 19
- 235000008434 ginseng Nutrition 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims description 52
- 230000036039 immunity Effects 0.000 claims description 35
- 230000002708 enhancing effect Effects 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 22
- 241001312741 Gekko swinhonis Species 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 241000208340 Araliaceae Species 0.000 claims description 18
- 241000756943 Codonopsis Species 0.000 claims description 18
- 241000628997 Flos Species 0.000 claims description 18
- 240000000588 Hericium erinaceus Species 0.000 claims description 17
- 235000007328 Hericium erinaceus Nutrition 0.000 claims description 17
- 244000309464 bull Species 0.000 claims description 17
- 240000001080 Grifola frondosa Species 0.000 claims description 16
- 235000007710 Grifola frondosa Nutrition 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 15
- 239000002552 dosage form Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 9
- 241000593508 Garcinia Species 0.000 claims description 8
- 235000000885 Garcinia xanthochymus Nutrition 0.000 claims description 8
- 241000545442 Radix Species 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 239000006196 drop Substances 0.000 claims description 6
- 230000003203 everyday effect Effects 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 6
- 230000003179 granulation Effects 0.000 claims description 6
- 235000011837 pasties Nutrition 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 4
- 238000007598 dipping method Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000000469 ethanolic extract Substances 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000012907 honey Nutrition 0.000 claims description 2
- 230000036571 hydration Effects 0.000 claims description 2
- 238000006703 hydration reaction Methods 0.000 claims description 2
- 238000007670 refining Methods 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 79
- 210000004369 blood Anatomy 0.000 abstract description 78
- 230000007812 deficiency Effects 0.000 abstract description 23
- 229940079593 drug Drugs 0.000 abstract description 18
- 230000017531 blood circulation Effects 0.000 abstract description 12
- 210000003734 kidney Anatomy 0.000 abstract description 12
- 230000004614 tumor growth Effects 0.000 abstract description 5
- 241001061264 Astragalus Species 0.000 abstract description 3
- 235000006533 astragalus Nutrition 0.000 abstract description 3
- 210000004233 talus Anatomy 0.000 abstract description 3
- 241000132012 Atractylodes Species 0.000 abstract description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 abstract 1
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract 1
- 241001189830 Fissistigma Species 0.000 abstract 1
- 241000598812 Garcinia tinctoria Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241001098499 Lanceolata Species 0.000 abstract 1
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 1
- 244000182216 Mimusops elengi Species 0.000 abstract 1
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 241000913745 Spatholobus Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 1
- 230000005784 autoimmunity Effects 0.000 abstract 1
- 235000017803 cinnamon Nutrition 0.000 abstract 1
- 235000015398 thunder god vine Nutrition 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 71
- 230000000694 effects Effects 0.000 description 56
- 201000011510 cancer Diseases 0.000 description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 37
- 201000010099 disease Diseases 0.000 description 32
- 210000000952 spleen Anatomy 0.000 description 26
- 238000002512 chemotherapy Methods 0.000 description 22
- 208000002193 Pain Diseases 0.000 description 18
- 230000036407 pain Effects 0.000 description 18
- 238000000034 method Methods 0.000 description 15
- 231100000614 poison Toxicity 0.000 description 15
- 230000001737 promoting effect Effects 0.000 description 15
- 239000009636 Huang Qi Substances 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 206010012735 Diarrhoea Diseases 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 235000009508 confectionery Nutrition 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 230000001093 anti-cancer Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 9
- 238000001959 radiotherapy Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 208000033809 Suppuration Diseases 0.000 description 8
- 210000001165 lymph node Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 239000002574 poison Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 210000001835 viscera Anatomy 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 230000002607 hemopoietic effect Effects 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 210000000779 thoracic wall Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- XQDBHSNYTFRCNJ-UDTLMCMUSA-N chembl525628 Chemical compound O([C@H]1[C@@H]2OC(=O)[C@](C)(O)CCC3=NC=CC=C3C(=O)OC[C@]3(C)O[C@]4([C@@]2(C)O)[C@H](OC(C)=O)[C@H]3[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@]4([C@H]1OC(C)=O)COC(=O)C)C(=O)C1=CC=CC=C1 XQDBHSNYTFRCNJ-UDTLMCMUSA-N 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000001882 diuretic effect Effects 0.000 description 4
- 201000006549 dyspepsia Diseases 0.000 description 4
- 230000008451 emotion Effects 0.000 description 4
- 239000003172 expectorant agent Substances 0.000 description 4
- 230000003419 expectorant effect Effects 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 208000037920 primary disease Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- IQUAVJOINYOCMR-UHFFFAOYSA-N wilfordine Natural products CC1c2ncccc2C(=O)OCC2(C)OC34C(OC(C)=O)C2C(OC(C)=O)C(OC(C)=O)C3(COC(C)=O)C(OC(C)=O)C(OC(=O)c2ccccc2)C(OC(=O)C1(C)O)C4(C)O IQUAVJOINYOCMR-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 208000007443 Neurasthenia Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- 208000005946 Xerostomia Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 208000000718 duodenal ulcer Diseases 0.000 description 3
- 201000005619 esophageal carcinoma Diseases 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 201000005917 gastric ulcer Diseases 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000007096 poisonous effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010049865 Achromotrichia acquired Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229920001491 Lentinan Polymers 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 150000004056 anthraquinones Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- -1 diterpenoid-lactone Chemical compound 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 2
- 210000003677 hemocyte Anatomy 0.000 description 2
- 229940000351 hemocyte Drugs 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940115286 lentinan Drugs 0.000 description 2
- 208000030208 low-grade fever Diseases 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 229960001252 methamphetamine Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000001989 nasopharynx Anatomy 0.000 description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 210000000216 zygoma Anatomy 0.000 description 2
- XWMMEBCFHUKHEX-MRTCRTFGSA-N (+)-Taraxasterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@H]2[C@@H]3[C@H](C)C(=C)CC[C@]3(C)CC[C@]21C XWMMEBCFHUKHEX-MRTCRTFGSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- QMKPCZNFLUQTJZ-UHFFFAOYSA-N (4aR)-10c-Hydroxy-1t.2c.4ar.6at.6bc.9.9.12ac-octamethyl-(8atH.12btH.14acH.14btH)-docosahydro-picen Natural products CC1CCC2(C)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C QMKPCZNFLUQTJZ-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241000269417 Bufo Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000289669 Erinaceus europaeus Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 240000003537 Ficus benghalensis Species 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000577951 Hydnum Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000019926 Keshan disease Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000222640 Polyporus Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000003130 cardiopathic effect Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 210000003109 clavicle Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000009200 cobalt therapy Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- WTYGAUXICFETTC-UHFFFAOYSA-N cyclobarbital Chemical compound C=1CCCCC=1C1(CC)C(=O)NC(=O)NC1=O WTYGAUXICFETTC-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 201000004637 gastric cardia carcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- XTLWNMXYCHABQH-UHFFFAOYSA-N germanicol Natural products CC1(C)CCC2(C)CCC3(C)C(CCC4(C)C5(C)CCC(O)C(C)(C)C5CCC34C)C2=C1 XTLWNMXYCHABQH-UHFFFAOYSA-N 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000010553 multiple abscesses Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000011309 nasal bleeding Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000021603 oncosis Effects 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108010001062 polysaccharide-K Proteins 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- NGFFRJBGMSPDMS-UHFFFAOYSA-N psi-Taraxasterol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(C)=CCC3(C)CCC21C NGFFRJBGMSPDMS-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- HUTYZQWCTWWXND-NCTFTGAASA-N taraxasterol Natural products C[C@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)C[C@H](O)[C@@]2(C)CCC1=C HUTYZQWCTWWXND-NCTFTGAASA-N 0.000 description 1
- GGGUGZHBAOMSFJ-GADYQYKKSA-N taraxerol Chemical compound CC([C@@H]1CC2)(C)[C@@H](O)CC[C@]1(C)[C@@H]1[C@]2(C)C2=CC[C@@]3(C)CCC(C)(C)C[C@H]3[C@]2(C)CC1 GGGUGZHBAOMSFJ-GADYQYKKSA-N 0.000 description 1
- HYTFUKZLSYXRDX-UHFFFAOYSA-N taraxerol Natural products CC1CCCC2C3(C)CCC4(C)C5CC(C)(C)CCC5(C)C=CC4(C)C3C(O)CC12C HYTFUKZLSYXRDX-UHFFFAOYSA-N 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- SWOVVKGLGOOUKI-ZHGGVEMFSA-N triptonide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)C(=O)[C@]21[C@H]3O1 SWOVVKGLGOOUKI-ZHGGVEMFSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种抗肿瘤及增强免疫力的中药制剂,所述中药制剂中各种组份的重量份数比为:人参10~30份,雷公藤2~7份,党参10~30份,黄芪10~30份,当归10~30份,乌骨藤10~30份,灰树花10~30份,何首乌10~30份,鸡血藤10~30份,蒲公英10~30份,蟾皮10~20份,天龙壁虎10~20份,红花10~30份,枸杞子10~30份,肉桂10~30份,猴头菇10~20份,白术10~30份,藤黄10~30份。本中药制剂经过科学配伍,能益肾补虚,活血养血,提高人体自身免疫力,活血化淤散结,能有效抑制肿瘤生长。
Description
技术领域
本发明涉及含有来源于植物、动物或矿物组份的医用配制品,特别涉及抗肿瘤及增强免疫力的中药制剂及其制备方法。
背景技术
中医学认为肿瘤总的病因为气滞血瘀痰凝,气行则血行,气滞则血瘀,气虚则血虚。痰亦因气化功能失常,水液未能输布、停聚、留滞而形成。饮食失调,手术损伤,病程日久皆可导致气血生化乏源、受损、虚弱。情志失常可致肝气郁结、气机不利;脾主运化升清,胃主受纳通降,气机失常影响脾胃功能,脾胃功能又可致气血生化不足,水湿痰饮形成。关于本病成因,古代医家多责之于虚、郁、痰、瘀四端。癌变过程的最根本原因是患病机体在癌变之前,伏有阴阳不和、脏腑失调、正气亏虚的潜在病因,复因情志、饮食、时令气候、地域等其它因素的长期刺激,使阴阳严重失调,脏腑功能极度紊乱,正气亏虚日笃,最终导致癌变。
癌症属于肿瘤病中之一恶性疾病,“癌”系古代“岩”、“”等字转化而来,因其形如岩石,累累坚硬,高突不平,故取其音义而名。中医认为本病多因饮食不节、七情(喜、怒、忧、思、悲、恐、惊)过度、等因素导致人体阴阳失调,热毒壅滞,气滞血瘀兼气血两虚而引起。《素问·通评虚实论》曰:“膈塞闭绝,上下不通,则暴忧之病也。”说明了噎膈的发病与暴忧有关。朱丹溪认为乳岩(癌)是“忧怒郁闷,朝夕积聚,脾气消阻,肝气横逆”所造成,《谵寮集验方》中说:“盖五积者,因怒、忧、思七情之气以伤五腑,遇传克不行而成病也。”说明由于七情过度可以影响五腑的功能,使之亏损,易招外邪入侵,也可使气机不畅,脉络受阻,气滞血瘀而成癌症。
近年来,随着生存环境的恶化污染,癌症已经成为人类健康的第一杀手。各种癌症的发病率上升很快。目前世界每年死于恶性肿瘤人数约700万,我国每年约160万新发肿瘤患者,105万死于此诱因。恶性肿瘤已经是城市中各种疾病死亡的第一位,并有逐年增加趋势。临床治疗恶性肿瘤的方法多种多样,包括手术治疗、放疗、化疗和中西医结合疗法等。
手术切除肿瘤虽然是最广泛、有效的手段之一,但对患者的创伤较大,且不能切除微小的亚临床病灶,还有瘤细胞脱落种植的可能;术后的放、化疗能杀灭残留癌细胞,也存在特异性较差、部分肿瘤细胞具有耐药现象等不足之处。西医放化疗,是恶性肿瘤的重要治疗方法之一。化学药物治疗恶性肿瘤自从1946年氮芥的应用以来基本形成一个完整的理论体系。但是由于大多数化学药物选择性差,用药后对正常组织和脏器的生理功能有一定的破坏作用,往往致化疗疗程不能完成等一系列毒副反应。主要表现为:骨髓抑制;消化道反应;免疫功能低下等。虽然现代医学各种防治化疗毒副反应的方法疗效肯定,如输血、利血升、造血生长因子、枢复宁等;但目前的这些方法也存在许多问题,如输血存在血源不足,血中致病因素越来越多限制它的使用;造血生长因子能促进白血病细胞繁殖,抑制细胞毒性化疗药物诱发急性白血病细胞凋亡,且不能解决化疗的骨髓外损害,故而对造血生长因子应用存在争议。同时,这些药物主要从单一角度起作用,整体调节效果不佳;且价格昂贵,临床使用受限。目前,中医对于恶性肿瘤治疗的研究多集中于提高机体免疫力,增强患者对放、化疗的敏感性,抑制癌细胞增殖和促进癌细胞凋亡等方面。
部分患者在放化疗后出现腹泻,经西药治疗后疗效不佳。放化疗时由于不能分清身体各器官有益细胞还是癌细胞,往往全部破坏,极大损伤病患身体。得癌症又因为本身中气不足,造成癌症患者在放化疗期间身体极其虚弱。由于放化疗常具有较多的毒副反应,以及患者的个体差异,使得部分患者难以接受全程放化疗,对治疗癌症效果大打折扣。随着高效抗肿瘤药物的不断出现,化疗在恶性肿瘤治疗中应用日益广泛。但化疗可不同程度地引起骨髓抑制,其中以寿命较短的白细胞的减少更为明显,从而影响化疗。凡化疗过程中,或在放射照射后,出现腹痛、腹泻、里急后重、血便症状,西医通常使用足量的抗生素如氟哌酸等抗菌药物治疗,似以祛邪为主,但疗效甚微。扶正固本,是临床治疗恶性肿瘤的常用中医治则。中医治疗往往见效慢,疗效差强人意,且针对性不强,周期漫长。至今为止,国内外尚未出现对本病的十分满意的治疗效果的方法与措施。为此,临床上迫切需要既能有效升血又能改善患者机能状态的药物。
发明内容
本发明所要解决的技术问题在于,提供一种抗肿瘤及增强免疫力的中药制剂及其制备方法,针对各种程度的肿瘤,以及市场上治疗癌症,肿瘤的药物疗效不理想,见效较慢的缺点,在传统医学的基础上结合多年临床经验,采用现代加工方法精心研制而成。本发明对组份药品的各有效成分科学配伍,是一种见效较快、效果持续久的中药制剂,内外结合,标本兼治,能一定程度上解决患者的痛苦;同时此药还可以与各种癌症的放疗、化疗中配合使用,具有增强疗效、减轻副作用的功效,提高患者的免疫力。
为解决上述技术问题,本发明提供一种配方简单、制作工艺简单抗肿瘤及增强免疫力的中药制剂,所述药物中各种组份的重量份数比为:人参10~30份,雷公藤2~7份,党参10~30份,黄芪10~30份,当归10~30份,乌骨藤10~30份,灰树花10~30份,何首乌10~30份,鸡血藤10~30份,蒲公英10~30份,蟾皮10~20份,天龙壁虎10~20份,红花10~30份,枸杞子10~30份,肉桂10~30份,猴头菇10~20份,白术10~30份,藤黄10~30份。
所述抗肿瘤及增强免疫力的中药制剂,各种组份的重量份数比可以优选为:人参10~15份,雷公藤3~5份,党参10~15份,黄芪10~15份,当归10~15份,乌骨藤10~20份,灰树花10~20份,何首乌10~15份,鸡血藤10~15份,蒲公英10~15份,蟾皮10~15份,天龙壁虎10~15份,红花10~20份,枸杞子10~15份,肉桂10~15份,猴头菇10~15份,白术10~15份,藤黄10~15份。
所述抗肿瘤及增强免疫力的中药制剂,各种组份的重量份数比还可以优选为:人参10~20份,雷公藤4~6份,党参10~20份,黄芪10~20份,当归10~20份,乌骨藤10~15份,灰树花10~15份,何首乌10~20份,鸡血藤10~20份,蒲公英10~15份,蟾皮10~15份,天龙壁虎10~15份,红花10~15份,枸杞子10~20份,肉桂10~15份,猴头菇10~15份,白术10~20份,藤黄10~20份。
所述抗肿瘤及增强免疫力的中药制剂,各种组份的重量份数比也可以优选为:人参15~25份,雷公藤3~7份,党参15~25份,黄芪15~25份,当归15~25份,乌骨藤10~25份,灰树花15~25份,何首乌10~25份,鸡血藤10~25份,蒲公英10~25份,蟾皮10~15份,天龙壁虎10~15份,红花15~25份,枸杞子15~25份,肉桂15~25份,猴头菇10~20份,白术15~25份,藤黄15~25份。
所述抗肿瘤及增强免疫力的中药制剂,在使用时煎汤剂服用,每日1剂,可以水煎分两次服,每7天为一疗程。
所述抗肿瘤及增强免疫力的中药制剂,药物的剂型还可以为:蜜炼丸剂、水合丸剂、胶囊、口服液、颗粒剂、胶剂、糖浆剂或滴剂。
所述抗肿瘤及增强免疫力的中药制剂,药物剂型为片剂或散剂,服用时,可以一天三次,每7天为一疗程。
为解决上述技术问题,本发明还提供了一种抗肿瘤及增强免疫力的中药制剂的制备方法,所述药物剂型为胶囊,其制备过程包括:
按照所述份数比将蟾皮和天龙壁虎用95%的乙醇浸泡三次,每次浸泡时间分别为2小时、1小时、1小时;每次浸泡后80~85℃热提取;所用乙醇与蟾皮和天龙壁虎的重量份数比分别为:第一次10倍量、第二次6倍量、第三次6倍量;合并三次乙醇提取液,浓缩至相对密度为1.06的浓缩液,静置备用;前述提取后的残渣与其他所述组份合并,80~100℃水煎煮三次,煎煮时间分别为2小时、1.5小时、1小时;所用水与残渣和其他组份总重量的重量份数比分别为:第一次10倍量、第二次8倍量、第三次6倍量;合并三次的煎煮液,浓缩至相对密度为1.08的浓缩液;再将煎煮浓缩液与乙醇浓缩液合并、过滤、喷雾干燥、制粒,装胶囊。
为解决上述技术问题,本发明又提供了一种抗肿瘤及增强免疫力的中药制剂的制备方法,所述药物剂型为粉剂,其制备过程包括:
将所述组份加水浸泡30分钟至1小时,加热煮30~40分钟,过滤,滤液备用;滤渣加水第二次加热,煮沸30~40分钟,过滤,滤液备用;滤渣再加水,第三次加热煮沸40~50分钟,过滤;将三次滤液合在一起,加热浓缩至糊状,放入烘箱80℃烘干后冷却,研磨成细粉状,即成粉剂中成药。
为解决上述技术问题,本发明再提供了一种抗肿瘤及增强免疫力的中药制剂的制备方法,所述药物剂型为粉剂,其制备过程包括:
将所述组份按配比混合,投入粉碎机粉碎成细粉,细粉过筛后放入耐酸碱浸渍锅内,在常温下,与乙醇共同浸渍15~30天,将浸渍好的液体及药渣进行压榨过滤,分离后取滤液,将滤液加热浓缩至糊状,放入烘箱烘干后冷却,研磨成细粉,即成粉剂中成药。
本发明采用不同药性的中药材,进行了科学配伍,能达到理想的治疗效果,且安全,能有效减轻病患痛苦,提高病人生活质量。对改善瘤体压迫引起的疼痛以及出血具有良好的临床疗效,并明显改善患者的精神、食欲、睡眠等一般状况,而且副作用小,治疗安全、方便,可减轻痛苦、延长生命,尤其对提高晚期癌症病人的生活质量效果显著。同时此药还可以与各种癌症的放疗、化疗中配合使用,具有增强疗效、减轻副作用的功效。对不能接受放疗、化疗、手术治疗的晚期癌症患者,此药是理想的选择。本发明使用方便,选用药材价格低廉,制造方法简单,能创造较好的社会价值及经济利益
具体实施方式
恶性肿瘤是严重威胁人类健康的一类常见疾病,寻找有效的抗癌药物和方法,是世界医学面临的重要课题。中药是祖国医学用来防治疾病的有力武器,人们发现中药治疗恶性肿瘤,无论是在减轻临床症状,提高生存质量,防止复发转移,延长生存期,还是在与放化疗配合,增效减毒等方面都有很好的效果。恶性肿瘤的发生发展是多因素、多阶段的复杂过程,各种肿瘤相关基因异常表达的长期积累是癌变过程中的重要环节。中药通过扶正为主,祛邪为辅,标本兼治的手段,既培补了脾气,又清除了湿热,也就是说,既调整了肠道菌群失调,又抑制了细菌的生长。保证了放化疗的继续进行,在恶性肿瘤的综合治疗中具有重要作用。
化疗药物或放射性治疗耗伤人体正气,伤脾败胃,使脾气虚弱,运化失职,脾失健运,胃失和降,水谷不归正化,生湿化热,水湿下趋大肠,湿热蕴结,致大肠传导功能失常。故见恶心呕吐及腹泻等症。正如《景岳全书泄泻》所谓“泄泻之本,无不由于脾胃。”本病之湿热,实由脾虚不能运湿,湿蕴化热而成,故其为标,而病之本则在脾气之虚。故治疗应以扶正为先,一旦正气恢复,邪气自然退却。标本兼顾,着重补气健脾以治其本,兼以清热化湿以治其标。
恶性肿瘤属中医瘕、积聚的范畴。祖国医学理论认为,癌(积)的发生与机体抗病能力(正气)的虚弱有密切关系。正气虚损为癌(积)发病的主要病因。《内经》云:“正气存内,邪不可干”,“邪之所凑,其气必虚”《外证医编》进一步发挥道“:正气虚则成岩”《,医学心法》也强调“积之成也,正气不足,而后邪气踞之”,都说明癌症的发生,多是在正虚的基础上产生的。正气虚弱,阴阳失调,脏腑虚衰,邪毒乘虚而入,邪正相争,正不胜邪,邪毒凝聚而成毒瘤,横溢流注,则瘤毒转移遍身。其病机特点为因虚而得病,因虚而致实。中医向来崇尚“治病必求于本”,何况中晚期癌症病人的正气虚损尤为突出,因此,确立扶正固本治则,从增强机体抗病能力着手,以驱除消灭肿瘤。诚如金·张子和所说:“正胜则邪却,邪去则正安”。癌症多以热毒壅盛,气滞血瘀,气血两亏为主要证候,故以清热解毒为主,辅以理气化瘀,补益气血为组方大法而组方,体现了中医辨证施治的特色;在药物的选用方面,不用峻厉之品,而以药性平和的药物,体现了用药安全、有效的“平中见奇”之用特点。本发明中药制剂配伍严谨,祛邪与扶正并施,共奏清热解毒、理气化瘀、补益气血、调理脾胃之功,故对癌症见有热毒壅盛,气滞血瘀,气血两虚,脾胃虚弱证用之能获效。以扶正固本为主治疗中晚期恶性肿瘤,可明显缓解症状,缩小瘤体,抑制肿瘤生长,防止肿瘤复发转移,改善生存质量,延长生存时间。
中医认为阳气未复,邪热炽盛,正邪交争,阴津耗损。温热病邪热炽盛,深入营血,与血互结,迫血妄行,或气血虚损,不能充盈脉道,血行缓慢而挟瘀。无论是瘀热阻络,还是血虚挟瘀,或气虚无力运血,或气滞不能行血,均导致了气血失调、血流瘀滞、瘀血。人参大补元气、健脾生津,《本草经疏》曰:“人参能回阳气于垂绝,却虚邪于俄顷。其主治也,则补五脏。”黄芪补中益气、利水生肌,《本经疏证》曰:“黄芪,直入中土而行三焦,故能内补中气。”二药合用,一则温煦全身,鼓舞气血,激发机体生命的活力;二则补气,气旺则血生,气旺则血行,既可增强体质,又可扶正以祛邪。现已发现,大凡虚证都有不同程度免疫功能低下或紊乱,而现代药理研究也表明人参具有抗肿瘤,增强和调节机体免疫功能的效用。人参皂苷及其单体Re、Rd在体外可增强免疫受抑小鼠的T细胞功能,并可调节细胞与体液免疫反应,可以通过诱导分化或凋亡抑制肿瘤细胞的增殖。黄芪多糖、皂苷能提高人体免疫功能,增强细胞生理代谢,提高巨噬细胞活性,是理想的免疫增强剂,它能促进T细胞、B细胞、NK细胞等免疫细胞的功能,对艾滋病等多种免疫缺陷症均有良好的防治作用,还有抑制EAS,双向调节血糖等作用,延缓细胞衰老,有利于延年益寿。当黄芪多糖与人参多糖配伍,可显著提高抗癌活性,降低化疗副作用,癌症患者化疗后使用该药,能明显升高白细胞的计数。
黄芪以补虚为主,能补气固表,利尿托毒,排脓,敛疮生肌。用于气血不足、疮疡内陷、脓成不溃或久溃不敛者。黄芪具有很好的托毒生肌的功能,即久不愈合的脓肿化脓生肌。现代医学研究表明,黄芪内含而多种抗菌有效成分,而且能增强机体的免疫功能,因此还能用于预防某些传染病的发生。《本草逢原》载:“黄芪能补五脏诸虚,治脉弦自汗,泻阴火,去肺热,无汗则发,有汗则止。”是增进抵抗力和防御疾病的良药。
枸杞是一味常用的补肝益肾,增强免疫力的中药。现代医学研究证实其含有甜菜硷、多糖、粗脂肪、粗蛋白、胡萝卜素、维生素A、维生素C、维生素B1、维生素B2及钙、磷、铁、锌、锰、亚油酸等营养成分,对造血功能有促进作用,还能抗衰老、抗突变、抗肿瘤、抗脂肪肝及降血糖等作用。中医常常用它来治疗肝肾阴亏、腰膝酸软、头晕、健忘、目眩、目昏多泪、消渴、白发,脱发,遗精等病症,滋阴养肾功效显著。
当归,其味甘而重,故专能补血,其气轻而辛,故又能行血,补中有动,行中有补,诚血中之气药,亦血中之圣药。大约佐之以补则补,故能养营养血,补气生精,安五脏,强形体,益神志,凡有形虚损之病,无所不宜。佐之以攻则通,故能祛痛通便,利筋骨,治拘挛、瘫痪、燥、涩等证。营虚而表不解者,佐以柴、葛、麻、桂等剂,大能散表卫热,而表不敛者,佐以大黄之类,又能固表。惟其气辛而动,故欲其静者当避之,性滑善行,大便不固者当避之。凡阴中火盛者,当归能动血,亦非所宜,阴中阳虚者,当归能养血,乃不可少。也是提高人体免疫力的良药。
党参性平,味甘、微酸。归脾、肺经。补中益气,健脾益肺。用于脾肺虚弱,气短心悸,食少便溏,虚喘咳嗽,内热消渴。《本草正义》载:党参力能补脾养胃,润肺生津,腱运中气,本与人参不甚相远。其尤可贵者,则健脾运而不燥,滋胃阴而不湿,润肺而不犯寒凉,养血而不偏滋腻,鼓舞清阳,振动中气,而无刚燥之弊。黄芪补气、既能升补脾气,又能益肺固表。党参补气,只能健脾补气,无固表之力,但党参还能益气生津,黄芪则无生津之效,黄芪兼能利水,党参无利水作用。这两味药合用最能补中益气,提高免疫力。
雷公藤,苦、辛,凉。有大毒。少量运用可治疗肿瘤。内含雷公藤碱、雷公藤定碱等多种生物碱、二萜内酯、雷藤酮及卫矛醇等。雷公藤碱、雷公藤定碱及二萜内酯、卫矛醇均有明显的抗肿瘤活性,对小鼠白血病1210,P388及人类鼻咽癌均有抑制作用动物试验和一些临床研究证明,雷公藤能抑制过快分裂增殖的肿瘤细胞,因此具有抗癌的作用。
乌骨藤性味苦,微寒,具有消炎、清热解毒、止咳平喘、散结止痛等功效,主产于云南.含有多种甾体酯苷、生物碱、有机酸、多糖、树脂及色素等多种化学成分,传统用于咳嗽哮喘、痰咳嗽喘,主治气管炎,支气管哮喘。具有免疫调节、保肝利尿、败毒抗癌等作用。而乌骨藤内含有的独特化学成分制备而成的中药消癌平,对胃癌、肝癌等多种肿瘤具有确切的抗肿瘤疗效,是一种很有前途的抗肿瘤中药。该植物中含有一种神秘的抗癌物质——乌骨消癌素(C21-甾体甙和乌骨总碱),它对癌细胞分裂的根源~微管排列有很强的破坏作用,能阻断癌细胞的有丝分裂,从而有效切断癌细胞扩散、转移,癌症因此而萎缩直至完全消失。
灰树花具有极高的医疗保健功能。据文献报导,它有抑制高血压和肥胖症的功效;由于富含铁、铜和维他命C,它能预防贫血、坏血病、白癜风,防止动脉硬化和脑血栓的发生;它的硒和铬含量较高,有保护肝脏、胰脏,预防肝硬化和糖尿病的作用;硒含量高使其还具有防治克山病、大骨节病和某些心脏病的功能;它兼含钙和维生素D,两者配合,能有效地防治佝偻病;较高的锌含量有利大脑发育、保持视觉敏锐,促进伤口愈合;高含量的维生素E和硒配合,使之能抗衰老、增强记忆力和灵敏度。灰树花还是引人注目的抗癌药源,一方面,较高的硒含量有抗御癌肿的作用,尤其是所含灰树花多糖(Grifolan),以β-葡聚糖(glucan)为主,其中抗癌活性最强,带6条支链的β-(1,3)-葡聚糖占相当大的比重,据说比已经面市的香菇多糖(Lentinan,日本的PSK,)、云芝多糖(上海的PSP)等有更强的抗癌能力;同时它又是极好的免疫调节剂。作为中药,灰树花和猪苓等效,可治小便不利、水肿、脚气、肝硬化腹水及糖尿病等,是非常宝贵的药用真菌。
何首乌性味苦、甘、涩,温。归肝、心、肾经。《本草纲目》记载“此物气温,味苦涩。苦补肾,温补肝,湿能收敛精气。所以能养血益肝,固精益肾,健筋骨,乌髭发,为滋补良药,不寒不燥,功在地黄、天门口冬绪药之上。”可治肝肾阴亏,发须早白。中医中药理论认为,何首乌性味苦、甘、涩,微温,具有补肝、益肾、养血、祛风等功效,适用于肝肾阴亏、须发早白、血虚头晕、腰膝酸软、筋骨酸痛、遗精、崩带、久痢、慢性肝炎、痈肿、瘰疬、肠风、痔疮、红斑狼疮等病症。现代医学证实,何首乌中的蒽醌类物质,具有降低胆固醇、降血糖、抗病毒、强心、促进胃肠蠕动等作用,还有促进纤维蛋白溶解活性作用,对心脑血管疾病有一定的防治作用;何首乌中所含卵磷脂是脑组织、血细胞和其他细胞膜的组成物质,经常食用何首乌,对神经衰弱、白发、脱发、贫血等病症有治疗作用,因此,可延缓衰老、强身健体、保健心脏。动物实验证明,何首乌还有抗肿瘤作用。同时,现代药理研究发现何首乌含有的卵磷脂、蒽醌衍生物及大黄酚等多种物质,能够抑制胆固醇的升高、减少胆固醇在肠道吸收,可防止胆固醇在组织中沉积,因而能缓解动脉粥样硬化的形成,临床研究证实其降胆固醇及甘油三酯总有效率达80%以上。何首乌还有强壮神经的作用,可健脑益智,能够促进血细胞的生长和发育,有显著的抗衰老作用。中年人经常食用何首乌,可防止早衰的发生和发展。
壁虎去内脏的干制品入中药,名“天龙壁虎”,有补肺肾、益精血、止咳定喘、镇痉祛风和发散消肿的功效,可治淋巴结核、神经痛、慢性关节炎、乳房肿块。味咸,寒。有小毒。主治祛风,活络,散结。用于中风瘫痪,风湿关节痛,骨髓炎,淋巴结结核,肿瘤。是治疗各种肿瘤的良药。
红花性温,味辛。功能主治应用于活血通径、散瘀止痛。用于经闭、痛经、恶露不行、症瘕痞块、跌打损伤。《本草汇言》:红花,破血、行血、和血、调血之药也。主胎产百病因血为患,或血烦血晕,神昏不语;或恶露抢心,脐腹绞痛;或沥浆难生,;或胞衣不落,子死腹中,是皆临产诸证,非红花不能治。若产后血晕、口噤指搦;或邪入血室,谵语发狂;或血闷内胀,僵仆如死,是皆产后诸证,非红花不能定。凡如经闭不通而寒热交作,或过期腹痛而紫黑淋漓,或跌扑损伤而气血瘀积,或疮疡痛痒而肿溃不安,是皆气血不和之证,非红花不能调。
肉桂性大热,味辛、甘。功能补火助阳,引火归源,散寒止痛,活血通经。用于阳痿、宫冷、心腹冷痛、虚寒吐泻、经闭、痛经、温经通脉。《别录》载其:主心痛,胁风,胁痛,温筋,通脉,止烦、出汗。主温中,利肝肺气,心腹寒热、冷疾,霍乱转筋,头痛,腰痛,止唾,咳嗽,鼻;能堕胎,坚骨节,通血脉,理疏不足;宣导百药,无所畏。现代医学研究其对中枢神经系统具有镇静作用。肉桂中含有的桂皮醛对小鼠有明显的镇静作用,表现为自发活动减少,对抗甲基苯丙胺(Methamphetamine)所产生的过多活动、转棒试验产生的运动失调以及延长环己巴比妥钠的麻醉时间等。应用小鼠压尾刺激或腹腔注射醋酸观察扭体运动的方法证明它有镇痛作用。所以是放疗化疗良好的辅助性药材。
猴头菇是一种药食两用真菌。猴头菌性平,味甘能利五脏、助消化、滋补、抗癌、治疗神经衰弱,国内已广泛应用于医治消化不良,胃溃疡,十二指肠溃疡、食道癌、胃癌等消化系统疾病。现代医学研究发现,猴头能抑制癌细胞中的遗传物质的合成,从而可以预防消化道癌症和其他恶性肿瘤。对胃溃疡、十二指肠溃疡、胃炎等消化道疾病的疗效令人瞩目。猴头菌具有较高的药用价值,助消化,利五脏,对胃溃疡、十二指肠溃疡及神经衰弱等有特异疗效,并能提高人体的免疫力。猴头菌中含有多糖、多肽类物质,对消化道中肿瘤有一定的治疗和抑制作用。
蟾皮,中药里也称蟾衣,是蟾蜍自然蜕下来的表皮包衣,能除顽恶肿瘤也,它乃其五脏六肺之精气,吸纳阴阳天地之华宝,用之治恶疾,未有不愈,摘自李时珍《本草纲目》,被专家公认为抗癌良药。抗癌药理:蟾毒内脂类物质对小鼠S180、兔B、P瘤、子宫颈癌14、腹水型肝癌等,均有抑制作用,在机体上能抑制人的颧上下颌未分化癌,均有抑制作用,在机体上能抑制人的颧上下颌未分化癌、间皮癌、胃癌、脾肉瘤、肝癌等肿瘤细胞的呼吸,在试管中,对白血病细胞有抑制作用。众所周知蟾酥是一种有毒中药,如果单用蟾酥过量容易引起中毒,而本发明使用蟾皮代替蟾酥,则既能起到抗肿瘤作用,又不至于象蟾酥一样不好控制含有抗肿瘤作用的肽类成分----抗癌肽,因此其抑瘤作用较强,但又不至于引起中毒。
藤黄消肿,化毒,止血,杀虫。治痈疽肿毒,顽癣恶疮,损伤出血,牙疳蛀齿,汤火伤。藤黄对金黄色葡萄球菌有较强的抑菌作用,醇溶液对绿脓杆菌有较强抑菌作用。藤黄酸对多种肿瘤显示较强的抗肿瘤活性,并在有效剂量范围内毒副作用比较小,对肿瘤细胞的抑制有非常高的选择性,能选择性地杀死癌细胞,而对正常动物造血系统和免疫功能没有影响,这是目前肿瘤化疗药物所不具备的。药代动力学研究亦显示,藤黄酸在肿瘤组织中有较高的分布和较长的持续时间。藤黄酸为广谱抗肿瘤药,对多种肿瘤有显著疗效。
鸡血藤性苦、甘,温。归肝、肾经,补血,活血,通络。用于月经不调,血虚萎黄,麻木瘫痪,风湿痹痛活血舒筋;养血调经,《本草纲目拾遗》载其能医手足麻木;肢体瘫痪;风湿痹痛;妇女有经不调;痛经。是一味补血活血的良药。
蒲公英是一味常用的中药,其药用价值早已载入各种医书。它全草入药,含蒲公英甾醇、蒲公英赛醇、蒲公英苦素、咖啡酸、胆碱、菊糖等成分。性平味甘微苦。可清热解毒,消肿散结。《本草纲目》记载:“解食毒,散滞气,清热毒,化食毒,消恶肿、结核、疔肿”。蒲公英昧甘平,其性无毒。当是入肝入胃,解热凉血排毒之要药。
白术味苦、甘,温。归脾、胃经。主治健脾益气,燥湿利水,止汗,安胎。用于脾虚食少,腹胀泄泻,痰饮眩悸,水肿,自汗,胎动不安。白术对瘤细胞有细胞毒作用,能降低瘤细胞的增殖率,减低瘤组织的侵袭性,提高机体抗肿瘤反应的能力。白术挥发油对小鼠艾氏腹水癌、淋巴肉瘤腹水型、食管癌(Eca109)、肉瘤180等有抑制作用。白术内酯B腹腔注射对小鼠肉瘤民。也有显著抑制作用。《药性论》载其:君,味甘,辛,无毒。能主大风痹,多年气痢,心腹胀痛,破消宿食,开胃,去痰涎,除寒热,止下泄。主面光悦,驻颜,去黑。治水肿胀满,吐呕逆,腹内冷痛,吐泻不住,及胃气虚冷痢。
本发抗肿瘤及提高免疫力的中药制剂的制备方法包括:药物剂型为胶囊时的制备方法由以下步骤组成:
蟾皮2000g,天龙壁虎2000g先经95%以上乙醇提取3次,即用乙醇浸泡,80~85℃热提取,时间分别为2小时、1小时、1小时,所用乙醇与蟾皮和天龙壁虎的重量比分别为:第一次为10倍量、第二次为6倍量、第三次为6倍量,合并三次浸泡后的乙醇提取液,然后回收乙醇,浓缩至相对密度为1.06,浓缩后的药液静置备用;残渣与其他药物按照本发明配比合并,水提3次,即水煎煮,80~100℃、时间分别为2小时、1.5小时、1小时,所用水与残渣和其他药物总重量的重量比分别为:第一次为10倍量、第二次为8倍量、第三次为6倍量,提取三次的水提液合并,浓缩(浓缩至相对密度为1.08);再将水提液与乙醇浓缩药液合并、滤过、喷雾干燥、制粒,装胶囊。
本发明粉剂中成药的制备方法,包括:
将人参3000g,党参3000g,黄芪3000g,当归3000g,雷公藤300g,乌骨藤3000g,灰树花3000g,何首乌3000g,鸡血藤3000g,蒲公英3000g份,蟾皮2000g,天龙壁虎2000g,红花3000g,枸杞子3000g,肉桂3000g,猴头菇2000g,白术3000g,藤黄3000g;加水20升浸泡45分钟,加热煮沸35分钟,过滤,滤液备用;滤渣加水第二次加热,煮沸35分钟,过滤,滤液备用;滤渣再加水,第三次加热煮沸45分钟,过滤;将三次滤液合在一起,加热浓缩至糊状,放入烘箱80℃烘干后冷却,研磨成细粉状;即成粉剂中成药,兑温开水冲服,一天两次。
本发明药剂的制备方法还可以为以下步骤:
将所述组份按配比混合,投入粉碎机粉碎成细粉,细粉过筛后放入耐酸碱浸渍锅内,在常温下,与酒精一起浸渍15~30天,将浸渍好的液体及药渣进行压榨过滤,分离后取滤液,将滤液加热浓缩至糊状,放入烘箱烘干后冷却,研磨成细粉状;即成粉剂中成药,兑温开水冲服,可以一天两次。
本中药制剂益肾补虚,活血养血,标本兼治,提高人体自身免疫力,调节神经系统,活血化淤散结,能有效抑制肿瘤生长,且成本低廉、制取工艺简便易行。本发明采用不同药性的中药材,进行了科学配伍,能达到理想的治疗效果,且安全,能减轻病患痛苦,提高病人生活质量。本发明使用方便,选用药材价格低廉,制造方法简单,能创造较好的社会价值及经济利益。对改善瘤体压迫引起的疼痛以及出血具有良好的临床疗效,并明显改善患者的精神、食欲、睡眠等一般状况,而且副作用小,治疗安全、方便,可减轻痛苦、延长生命,尤其对提高晚期癌症病人的生活质量效果显著。同时此药还可以与各种癌症的放疗、化疗中配合使用,具有增强疗效、减轻副作用的功效。对不能接受放疗、化疗、手术治疗的晚期癌症患者,此药是理想的选择。
药理学毒性试验
1.皮肤刺激性试验
取家兔剃毛,用本发明药剂散剂为例,进行诱导和激发接触试验,在24小时和48小时后观察试验家兔,均不见皮肤有红斑及水肿等现象,与阴性对照组无差异。结果表明,该贴剂对皮肤反应强度近于零,即无皮肤变态反应。
2.药物蓄积毒性试验报告
试验方法:选用20只健康小白鼠,雌、雄各10只,剂量设计每5天为一期,每期剂量分别为0.10LD50、0.15LD50、0.22LD50、0.34LD50、0.50LD50,此样品的雌性、雄性小鼠的LD50均为5000m份/k份BW(五个剂量为500、750、1100、1700、2500m份/k份BW)。每5天称体重一次,调整给药量,按0.1ml/10份BW经口灌胃。20天后,动物无死亡情况发生,试验结束,按递增剂量给受试物20天后,雌性、雄性动物均无死亡情况发生。
长期毒性试验,以40、20、10ml/kg(分别相当于临床拟用日剂量的67、33、17倍)给大鼠连续灌服60天,未见明显毒性反应,心、肝、肺、肾、肾上腺等主要脏器组织学检查未见明显病变。
3.急性毒性试验
以本品内服药物临床日用量的300倍给白鼠口服投药,观察5日。结果所有动物健存,其活动、饮食、毛发、排泄物未发现异常,未见毒性反应。对白鼠破损皮肤进行刺激性试验,未见有刺激性反应和其它不良反应。
毒性试验证明,该药未有毒副作用和不良反应,临床应用安全可靠。
药效学试验
1、动物与瘤株:♀NIH小鼠(18~20)g,♂ICR小鼠(18~20)g。
瘤株:小鼠肉瘤(S180)、EAC实体瘤。方法:建立小鼠脾虚模型大黄芒硝按生药重量4∶1配制。煎剂含生药1.0/gml。每日予小鼠灌胃0.3ml,持续1周,对照组灌胃等量生理盐水。
模型建立(即小鼠出现大便溏薄、行动迟缓、毛色无光泽等)后次日接种瘤株。取传代接种后9天种鼠,无菌条件下剥离瘤块,灭菌生理盐水1∶3制成匀浆,再调至含瘤细胞6×107/ml,接种于脾虚小鼠右侧腋窝皮下,每鼠0.2ml;EAC癌(实体型)5×106/ml瘤细胞,每鼠右腹皮下接种0.2ml。以上瘤种接种前均用0.2%台盼兰染色,计活细胞数≥90%。
2、实验分组
接种次日,将小鼠随机分成3组,每组10只,每日腹腔给药1次,连续10天。1组灌注生理盐水;2组灌注本发明注射液12ml/kg;3组灌注CTX(cytoxan)20mg/kg。以上均用生理盐水稀释成0.4ml。检测指标肿瘤生长抑制率:停药后次日,处死全部动物,剥取瘤块,称重,计算抑瘤率。肿瘤生长抑制率=(治疗组瘤重-对照组瘤重)/对照组瘤重×100%。结果表明,本发明具有明显的抗肿瘤生长性,抑制率高达88%。
实施例1:秦女士,41岁,2004年患乳腺癌,手术切除后转移肺癌,长期进行放化疗治疗,由于药物毒性作用,免疫力严重低下,多年来白细胞数只有2000多个,人也常年卧床不起,十分痛苦。使用如下药物治疗:
人参15g,雷公藤5g,党参15g,黄芪15g,当归15g,乌骨藤20g,灰树花20g,何首乌15g,鸡血藤15g,蒲公英15g,蟾皮15g,天龙壁虎15g,红花20g,枸杞子15g,肉桂15g,猴头菇15g,白术15g,藤黄15g。
煎汤剂服用,每日1剂,水煎分两次服,每7天为一疗程。服用3个疗程后精神好转,骨骼疼痛消失,服用8个疗程后可下地走路,服用12个疗程后能独立上下6楼,服用约30个疗程后白血球恢复到6000左右,现在精神饱满的开始上班工作了。
实施例2:沈女士,55岁,患者2005年4月左乳房上方发现一肿物,呈针刺样疼痛,同年6月在医院取组织活检,证实为左乳导管浸润癌,即行根治术,2005年8月,患者发现右侧切口胸骨旁处有一肿块隆起,皮色不红,亦无痛感,于同年11月底至某肿瘤医院诊治。当时检查患者左侧胸骨旁有一肿物高出皮肤,约3×5厘米,胸壁溃破。用姑息放疗后,左锁骨上窝淋巴结消失,左胸前皮肤出现纤维化,左胸壁湿性脱皮区约5×5厘米,内有一溃疡面约2×2厘米大小,右腋下扪及一淋巴结约1.5平方厘米,经治疗无效。遂至我院就诊。患者自述,近2年来每至午后发热,左胸壁溃疡面呈阵发性疼痛,痛剧时全身汗出,难以忍受,服止痛药后,痛止,逾时疼痛复发,左手臂内侧肿胀,左上肢活动受限,影响日常生活,饮食下降,口干咽痛,睡眠欠佳,小便色赤,大便干燥。检视患者面部虚浮:面色晦暗无化,两颧潮红,左胸壁溃烂面达6×6×1.2厘米,无分泌物,四周坏死组织僵硬黧黑,胸骨柄左缘损坏色黑,第3、2肋软骨坏死折断发黑,约呈八字形,可见心脏及大血管博动,左胸前皮肤纤维化。胸透阴性,肝功能未见异常。舌苔薄质红无津液,脉象细弦,重按力不足,中医辨证病人由热毒内蕴,耗伤阴液所致,使用如下药物治疗:
人参30g,雷公藤7g,党参30g,黄芪30g,当归30g,乌骨藤30g,灰树花30g,何首乌30g,鸡血藤30g,蒲公英30g,蟾皮20g,天龙壁虎20g,红花30g,枸杞子30g,肉桂30g,猴头菇20g,白术30g,藤黄30g。
服用四个疗程后,患者左胸壁溃烂处分泌物由灰白色清稀样脓水转为黄稠脓液,其疮面明显缩小,新生组织表面平整光洁,形成疤痕,仅在胸骨柄左缘残留黑色坏死组织两小块,有少量的稠粘的黄色脓液分泌,有时隐隐作痛,偶有低热,再服用3个疗程后复查见胸骨柄左上缘有一0.2×0.4×0.1厘米坏死组织自行脱落,未见出血。其他症状其本好转。此次月经也如期而至,经色红未见块,小腹已不痛。再守方服5月后,症状完全消失,乳房部触诊未见异常,B超检查,右乳房部未见异常。随访1年未复发。
实施例3:郑某,男,42岁。患者2002年3月发现鼻腔出血,时愈时发,同时12月18日在医院病理检查诊断:鼻咽低分化鳞癌。症见:鼻塞,头痛,视力减弱,口干,耳鸣,舌苔黄腻,脉滑数。查颈部淋巴结肿大约鸡蛋大小,质硬,活动差。证属:肺气不足,毒邪侵袭,气滞血瘀,痰湿凝聚。治宜:疏肝解郁,清热泻火,除湿化痰。使用如下配方医治:
人参25g,雷公藤5g,党参15g,黄芪15g,当归15g,乌骨藤25g,灰树花15g,何首乌25g,鸡血藤25g,蒲公英25g,蟾皮15g,天龙壁虎10g,红花15g,枸杞子25g,肉桂15g,猴头菇20g,白术25g,藤黄15g。
水煎服15剂。同时配合60钴治疗,每日7GY,共5600拉德。二诊(20033年2月7日):颈部淋巴结明显缩小,头痛鼻血消失,但仍鼻塞,鼻涕稠,耳鸣,口干,舌苔厚腻,饮食无味。继续服用本发明四个疗程,并配合放疗。三诊(2003年6月8日):药后经复查鼻咽部肿瘤消失,颈部淋巴结未触及,身体状况恢复良好。再以前药五疗程,以巩固之。2008年9月3日随访,患者治疗至今近5年,临床告愈。
实施例4:潘某,男,39岁,2005年11月19日其妻慕名来诊。一年前出现不明原因的持续低热,经医院诊断为恶性淋巴瘤,以“COTP”方案及“COHP”方案,化疗6疗程,效果不佳,同年10月4日转入上海某医院治疗,确诊为非何杰金氏淋巴瘤伴肺部感染。并以CTX、泰素等国际新药组合的新方案,化疗3疗程,疗效不满意,医院两次下病危通知,于2005年11月12日出院,其妻代诉:左颈部数个蚕豆大小淋巴结,质硬,活动差,腋下、腹股沟花生米大的肿大淋巴结数个,质硬不活动,伴腹膜后淋巴结肿大,头部疼痛欲裂,发热40℃以上数日,伴咳嗽,痰粘色黄,难咯,纳呆,失眠,便结。此为肝气郁结,郁久化热伤肺络之象。使用如下配方治疗:
人参15g,雷公藤5g,党参15g,黄芪20g,当归20g,乌骨藤20g,灰树花20g,何首乌15g,鸡血藤15g,蒲公英25g,蟾皮15g,天龙壁虎15g,红花20g,枸杞子15g,肉桂15g,猴头菇15g,白术20g,藤黄15g。
连服十疗程。连服2个月。二诊:发热已退,疼痛减轻,诸症已减,精神良好,亲自乘火车来榕复诊,舌苔黄,脉滑。此为痰火互结,肝气郁滞,仍以上方药加减,服用8疗程。后至总结材料时,随访患者,药服完诸症消失,人若常人,健康生活。
本发明对,对于各种肿瘤以及消化道癌症,食道癌、贲门癌、胃癌、肝癌、大肠癌、肺癌、鼻咽癌、乳腺癌、宫颈癌等均有显著疗效,尤其对肝癌、肝硬化腹水、肺癌有明显效果。经120余例患者的临床观察,有效率91%,好转率88%,且受试患者均为肿瘤,癌症患者,饮食困难,身体极度虚弱,部分癌症患者已多处扩散,用本制剂后数天即开始气机调畅,气血和调,达到以毒攻毒、通络止痛治其标,阻断肿瘤血管生成、提高机体免疫力以治其本,大大改善肿瘤患者的生存质量,部分患者已痊愈,表现出前所未有治疗效果。
Claims (10)
1、一种抗肿瘤及增强免疫力的中药制剂,其特征在于,所述中药制剂中各种组份的重量份数比为:人参10~30份,雷公藤2~7份,党参10~30份,黄芪10~30份,当归10~30份,乌骨藤10~30份,灰树花10~30份,何首乌10~30份,鸡血藤10~30份,蒲公英10~30份,蟾皮10~20份,天龙壁虎10~20份,红花10~30份,枸杞子10~30份,肉桂10~30份,猴头菇10~20份,白术10~30份,藤黄10~30份。
2、根据权利要求1所述抗肿瘤及增强免疫力的中药制剂,其特征在于,所述中药制剂中各种组份的重量份数比为:人参10~15份,雷公藤3~5份,党参10~15份,黄芪10~15份,当归10~15份,乌骨藤10~20份,灰树花10~20份,何首乌10~15份,鸡血藤10~15份,蒲公英10~15份,蟾皮10~15份,天龙壁虎10~15份,红花10~20份,枸杞子10~15份,肉桂10~15份,猴头菇10~15份,白术10~15份,藤黄10~15份。
3、根据权利要求1所述抗肿瘤及增强免疫力的中药制剂,其特征在于,所述中药制剂中各种组份的重量份数比为:人参10~20份,雷公藤4~6份,党参10~20份,黄芪10~20份,当归10~20份,乌骨藤10~15份,灰树花10~15份,何首乌10~20份,鸡血藤10~20份,蒲公英10~15份,蟾皮10~15份,天龙壁虎10~15份,红花10~15份,枸杞子10~20份,肉桂10~15份,猴头菇10~15份,白术10~20份,藤黄10~20份。
4、根据权利要求1所述抗肿瘤及增强免疫力的中药制剂,其特征在于,所述中药制剂中各种组份的重量份数比为:人参15~25份,雷公藤3~7份,党参15~25份,黄芪15~25份,当归15~25份,乌骨藤10~25份,灰树花15~25份,何首乌10~25份,鸡血藤10~25份,蒲公英10~25份,蟾皮10~15份,天龙壁虎10~15份,红花15~25份,枸杞子15~25份,肉桂15~25份,猴头菇10~20份,白术15~25份,藤黄15~25份。
5、根据权利要求1所述抗肿瘤及增强免疫力的中药制剂,其特征在于,所述中药制剂在使用时煎汤剂服用,每日1剂,水煎分两次服,每7天为一疗程。
6、根据权利要求1所述抗肿瘤及增强免疫力的中药制剂,其特征在于,所述中药制剂的剂型为:蜜炼丸剂、水合丸剂、胶囊、口服液、颗粒剂、胶剂、糖浆剂或滴剂。
7、根据权利要求1所述抗肿瘤及增强免疫力的中药制剂,其特征在于,所述药物剂型为片剂或散剂,服用时,一天三次,每7天为一疗程。
8、一种如权利要求1所述抗肿瘤及增强免疫力的中药制剂的制备方法,其特征在于,所述药物剂型为胶囊,其制备过程包括:
按照所述份数比将蟾皮和天龙壁虎用95%的乙醇浸泡三次,每次浸泡时间分别为2小时、1小时、1小时;每次浸泡后80~85℃热提取;所用乙醇与蟾皮和天龙壁虎的重量份数比分别为:第一次10倍量、第二次6倍量、第三次6倍量;合并三次乙醇提取液,浓缩至相对密度为1.06的浓缩液,静置备用;前述提取后的残渣与其他所述组份合并,80~100℃水煎煮三次,煎煮时间分别为2小时、1.5小时、1小时;所用水与残渣和其他组份总重量的重量份数比分别为:第一次10倍量、第二次8倍量、第三次6倍量;合并三次的煎煮液,浓缩至相对密度为1.08的浓缩液;再将煎煮浓缩液与乙醇浓缩液合并、过滤、喷雾干燥、制粒,装胶囊。
9、一种如权利要求1所述抗肿瘤及增强免疫力的中药制剂的制备方法,其特征在于,所述药物剂型为粉剂,其制备过程包括:
将所述组份加水浸泡30分钟至1小时,加热煮30~40分钟,过滤,滤液备用;滤渣加水第二次加热,煮沸30~40分钟,过滤,滤液备用;滤渣再加水,第三次加热煮沸40~50分钟,过滤;将三次滤液合在一起,加热浓缩至糊状,放入烘箱80℃烘干后冷却,研磨成细粉状,即成粉剂中成药。
10、一种如权利要求1所述抗肿瘤及增强免疫力的中药制剂的制备方法,其特征在于,所述药物剂型为粉剂,其制备包括:
将所述组份按配比混合,投入粉碎机粉碎成细粉,细粉过筛后放入耐酸碱浸渍锅内,在常温下,与乙醇共同浸渍15~30天,将浸渍好的液体及药渣进行压榨过滤,分离后取滤液,将滤液加热浓缩至糊状,放入烘箱烘干后冷却,研磨成细粉,即成粉剂中成药。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101188093A CN101518594B (zh) | 2009-03-02 | 2009-03-02 | 一种抗肿瘤及增强免疫力的中药制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101188093A CN101518594B (zh) | 2009-03-02 | 2009-03-02 | 一种抗肿瘤及增强免疫力的中药制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101518594A true CN101518594A (zh) | 2009-09-02 |
CN101518594B CN101518594B (zh) | 2012-05-23 |
Family
ID=41079525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009101188093A Expired - Fee Related CN101518594B (zh) | 2009-03-02 | 2009-03-02 | 一种抗肿瘤及增强免疫力的中药制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101518594B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103520279A (zh) * | 2013-10-16 | 2014-01-22 | 山东大学 | 樟属植物提取物在制备治疗或预防肿瘤的药物或保健品中的应用 |
CN104351557A (zh) * | 2014-11-24 | 2015-02-18 | 界首市全满养殖专业合作社 | 一种鱼饲料及其制备方法 |
CN105833042A (zh) * | 2016-05-12 | 2016-08-10 | 延君华 | 一种预防医院感染的中药制剂及其制备方法 |
CN105902669A (zh) * | 2016-04-29 | 2016-08-31 | 张萌 | 一种促进肿瘤压迫手术后愈合的复方制剂 |
CN111249406A (zh) * | 2020-03-19 | 2020-06-09 | 杭州憶盛医疗科技有限公司 | 一种抗肿瘤组合药物增强剂及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1054289C (zh) * | 1994-07-01 | 2000-07-12 | 柳毅 | 一种治疗肿瘤的药物 |
CN1216626C (zh) * | 2002-08-01 | 2005-08-31 | 黄爱强 | 一种祛瘀散结的抗癌胶囊 |
-
2009
- 2009-03-02 CN CN2009101188093A patent/CN101518594B/zh not_active Expired - Fee Related
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103520279A (zh) * | 2013-10-16 | 2014-01-22 | 山东大学 | 樟属植物提取物在制备治疗或预防肿瘤的药物或保健品中的应用 |
CN104351557A (zh) * | 2014-11-24 | 2015-02-18 | 界首市全满养殖专业合作社 | 一种鱼饲料及其制备方法 |
CN105902669A (zh) * | 2016-04-29 | 2016-08-31 | 张萌 | 一种促进肿瘤压迫手术后愈合的复方制剂 |
CN105833042A (zh) * | 2016-05-12 | 2016-08-10 | 延君华 | 一种预防医院感染的中药制剂及其制备方法 |
CN111249406A (zh) * | 2020-03-19 | 2020-06-09 | 杭州憶盛医疗科技有限公司 | 一种抗肿瘤组合药物增强剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101518594B (zh) | 2012-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101342271B (zh) | 医治肿瘤化疗引起的气血两虚的中药及制备方法 | |
CN105920514A (zh) | 治疗代谢综合征的中药组合物 | |
CN103736072B (zh) | 一种治疗过敏性鼻炎的药物及其制备方法 | |
CN101518594B (zh) | 一种抗肿瘤及增强免疫力的中药制剂及其制备方法 | |
CN101711848B (zh) | 一种辅助治疗肿瘤的中药组合物 | |
CN104524335A (zh) | 一种用于女性内分泌失调调理的药丸及制备方法 | |
CN102178818B (zh) | 一种治疗乳腺癌的中药组合物及其制备方法 | |
CN101518593B (zh) | 一种治疗乳腺增生及抗肿瘤的中药组合物及其制备方法 | |
CN101342357B (zh) | 治疗乳腺增生及防治乳腺癌的中药组合物 | |
CN101564464B (zh) | 一种调节肿瘤患者机体免疫力的中药药物 | |
CN105232987A (zh) | 一种促进神经外科术后康复的中药 | |
CN105381424A (zh) | 一种用于人体脏腑排毒的中药剂及制备方法 | |
CN103520697A (zh) | 治疗气阴不足证型胸痹心痛的中药 | |
CN103860773A (zh) | 用于治疗心肌缺血的中药组合物及其制备方法 | |
CN103705733B (zh) | 一种治疗心律不齐的中药胶囊及其制备方法 | |
CN102091254B (zh) | 一种用于面部整容后消肿的中药组合物及其制备方法 | |
CN104840773A (zh) | 治疗椎动脉型颈椎病的中药组合物及制法 | |
CN105770760A (zh) | 主治胃溃疡的制剂及其制备方法 | |
CN104225311A (zh) | 神经衰弱补益心脾药剂及制法 | |
CN104707003B (zh) | 治疗高血压、高血脂的中药胶囊 | |
CN105456933A (zh) | 一种活血化瘀、通经活络的中药及其制备方法 | |
CN104800457A (zh) | 一种治疗胃癌的软坚散结剂及制法 | |
CN101698088B (zh) | 治疗人体组织增生的中药 | |
CN105395872A (zh) | 一种用于抗化疗副反应的健脾和胃口服液 | |
CN102058818A (zh) | 虫草壁虎抗癌粉 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120523 Termination date: 20130302 |